IL-2 Variant Mutations Reduce CD122 Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for novel IL-2-based agents that are safe and efficacious for treating diseases, as existing IL-2 therapies are limited by severe toxicity and only benefit a small subset of eligible patients due to adverse effects such as fever, nausea, and hypotension.
Innovation Solution
Development of IL-2 agents with specific amino acid alterations that stabilize the protein, reduce affinity for CD122, and have minimal effect on CD25 affinity, enhancing regulatory T cell activity to treat autoimmune diseases and transplantation rejections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type IL-2 is used for treatment, then therapeutic efficacy is achieved, but severe toxicity occurs
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (H16L/N, I92S, V69A, Q74P, C125S) into the IL-2 protein sequence to alter its binding characteristics. These mutations modify the protein's affinity for CD122 and CD25 receptors, changing the pharmacological parameters to reduce toxicity while maintaining efficacy. The mutations specifically reduce affinity for CD122 (reducing vascular leak syndrome) while preserving affinity for CD25 (maintaining Treg activation).
Solution Approach 2:
The patent applies local quality by making targeted modifications at specific locations within the IL-2 protein structure. Rather than altering the entire protein, the invention introduces point mutations at specific amino acid positions (H16, I92, V69, Q74, C125) that are critical for receptor binding. This localized modification approach allows selective alteration of binding affinity to specific receptors while preserving overall protein function and stability.
2Reliability
If IL-2 therapy is administered to eligible patients, then disease treatment is achieved, but severe adverse effects limit the subset of patients who can receive therapy
Solution Approach 1:
The patent applies parameter changes by modifying the pharmacological profile of IL-2 through specific amino acid mutations. The H16L/N and I92S mutations reduce affinity for CD122, while V69A, Q74P, and C125S mutations maintain or enhance affinity for CD25. This parameter modification creates a version of IL-2 that is better tolerated by patients with autoimmune diseases and transplantation recipients, expanding the eligible patient population while maintaining treatment efficacy.
3Object-affected harmful factors
If IL-2 affinity for CD122 is reduced, then toxicity is decreased, but affinity for CD25 must be maintained to preserve Treg activity
Solution Approach 1:
The patent applies local quality by introducing distinct mutations at different locations within the IL-2 protein to achieve differential binding affinities. Mutations H16L/N and I92S are introduced to reduce CD122 binding (lowering toxicity), while mutations V69A, Q74P, and C125S are introduced to maintain or enhance CD25 binding (preserving Treg activity). This spatially distributed mutation strategy allows independent optimization of binding to different receptor types.
Solution Approach 2:
The patent applies parameter changes by systematically modifying the binding affinity parameters of IL-2 for different receptors through specific amino acid substitutions. The mutations are designed to change the binding kinetics and affinity constants specifically for CD122 (reducing it) while maintaining or enhancing affinity for CD25. This parameter optimization enables selective reduction of toxicity pathways while preserving therapeutic activity through Treg activation.
Data Source
AI summary
IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.